Evidence map›Paper›PMID 37226207›Full record

ArticleAlzheimer's research & therapy2023

Arterial hypertension and β-amyloid accumulation have spatially overlapping effects on posterior white matter hyperintensity volume: a cross-sectional study.

Jose Bernal, Stefanie Schreiber, Inga Menze, Anna Ostendorf, Malte Pfister, Jonas Geisendörfer, Aditya Nemali, Anne Maass, Renat Yakupov, Oliver Peters and 35 more

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Hypertension and cerebral blood flow in the development of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors at 16 institutions in 3 countries.

Jose Bernal *Institute of Cognitive Neurology and Dementia Research, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany. jose.bernalmoyano@dzne.de.
Stefanie Schreiber *German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
Inga MenzeInstitute of Cognitive Neurology and Dementia Research, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany.
Anna OstendorfInstitute of Cognitive Neurology and Dementia Research, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany.
Malte PfisterDepartment of Neurology, Medical Faculty, University Hospital Magdeburg, Magdeburg, Germany.
Jonas GeisendörferDepartment of Neurology, Medical Faculty, University Hospital Magdeburg, Magdeburg, Germany.
Aditya NemaliInstitute of Cognitive Neurology and Dementia Research, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany.
Anne MaassGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
Renat YakupovGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
Oliver PetersGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Lukas PreisCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität Zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany.
Luisa SchneiderCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität Zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany.
Ana Lucia HerreraCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität Zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany.
Josef PrillerGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Eike Jakob SpruthGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Slawek AltensteinGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Anja SchneiderGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Klaus FliessbachGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Jens WiltfangGerman Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany.
Björn H SchottGerman Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany.
Ayda RostamzadehDepartment of Psychiatry, University of Cologne, Cologne, Germany.
Wenzel GlanzInstitute of Cognitive Neurology and Dementia Research, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany.
Katharina BuergerGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Daniel JanowitzInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
Michael EwersGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Robert PerneczkyGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Boris-Stephan RauchmannDepartment of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.
Stefan TeipelGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Ingo KilimannGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Christoph LaskeGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Matthias H MunkGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Annika SpottkeGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Nina RoyGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Laura DobischGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
Peter DechentMR-Research in Neurosciences, Department of Cognitive Neurology, Georg-August-University Goettingen, Göttingen, Germany.
Klaus SchefflerDepartment for Biomedical Magnetic Resonance, University of Tübingen, Tübingen, Germany.
Stefan HetzerBerlin Center for Advanced Neuroimaging, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Steffen WolfsgruberGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Luca KleineidamGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Matthias SchmidGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Moritz BergerInstitute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany.
Frank JessenGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Miranka WirthGerman Center for Neurodegenerative Diseases (DZNE), Tatzberg 41, Dresden, 01307, Germany. miranka.wirth@dzne.de.
Emrah Düzel *Institute of Cognitive Neurology and Dementia Research, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany.
Gabriel Ziegler *Institute of Cognitive Neurology and Dementia Research, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany.
German Center for Neurodegenerative Diseases · DEOtto-von-Guericke University Magdeburg · DECharité - Universitätsmedizin Berlin · DEUniversity Hospital Magdeburg · DEUniversity of Bonn · DELudwig-Maximilians-Universität München · DEUniversity of Cologne · DEUniversity of Göttingen · DEUniversity of Tübingen · DEHertie Institute for Clinical Brain Research · DEHumboldt-Universität zu Berlin · DELMU Klinikum · DEMunich Cluster for Systems Neurology · DEUniversity Hospital Bonn · DEUniversity of Rostock · DEZimmer Biomet (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhite matter hyperintensities (WMH) in subjects across the Alzheimer's disease (AD) spectrum with minimal vascular pathology suggests that amyloid pathology-not just arterial hypertension-impacts WMH, which in turn adversely influences cognition. Here we seek to determine the effect of both hypertension and Aβ positivity on WMH, and their impact on cognition.

methodsWe analysed data from subjects with a low vascular profile and normal cognition (NC), subjective cognitive decline (SCD), and amnestic mild cognitive impairment (MCI) enrolled in the ongoing observational multicentre DZNE Longitudinal Cognitive Impairment and Dementia Study (n = 375, median age 70.0 [IQR 66.0, 74.4] years; 178 female; NC/SCD/MCI 127/162/86). All subjects underwent a rich neuropsychological assessment. We focused on baseline memory and executive function-derived from multiple neuropsychological tests using confirmatory factor analysis-, baseline preclinical Alzheimer's cognitive composite 5 (PACC5) scores, and changes in PACC5 scores over the course of three years (ΔPACC5).

resultsSubjects with hypertension or Aβ positivity presented the largest WMH volumes (p

conclusionsPosterior white matter is susceptible to hypertension and Aβ accumulation. Posterior WMH mediate the association between these pathologies and cognitive dysfunction, making them a promising target to tackle the downstream damage related to the potentially interacting and potentiating effects of the two pathologies.

trial registrationGerman Clinical Trials Register (DRKS00007966, 04/05/2015).

Indexed as

Alzheimer DiseaseHypertensionWhite MatterAgedAmyloid beta-PeptidesCross-Sectional StudiesFemaleHumansAmyloid beta-PeptidesAlzheimer’s diseaseCognitive performanceMRIVascular riskWhite matter hyperintensities

Identifiers

PMID37226207
PMCPMC10207740
OpenAlexW4378072210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.